3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Head & Neck
1
Genitourinary
1
Gastrointestinal
1
Dermatologic
1
Conditions
Carcinoma, Non-Small-Cell Lung
4
Squamous Cell Carcinoma of Head and Neck
2
Small Cell Lung Carcinoma
2
Prostatic Neoplasms
2
Melanoma
2
Colorectal Neoplasms
2
Uterine Cervical Neoplasms
1
Prostatic Neoplasms, Castration-Resistant
1
Primary Myelofibrosis
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Myeloproliferative Disorders
1
Myelodysplastic Syndromes
1
Multiple Myeloma
1
Lymphoma, Non-Hodgkin
1
Lymphoma, Large B-Cell, Diffuse
1
Lymphoma
1
Leukemia
1
Glioblastoma
1
Esophageal Squamous Cell Carcinoma
1
Carcinoma, Small Cell
1
Carcinoma, Hepatocellular
1
Breast Neoplasms
1
Anus Neoplasms
1
Interventions
Cisplatin
6
Etoposide
5
Topotecan
4
Carboplatin
4
Pemetrexed
3
Gemcitabine
3
belinostat
2
Temozolomide
2
RRx-001
2
vosaroxin
1
vinflunine
1
veliparib
1
taxane
1
sagopilone
1
sacituzumab govitecan
1
pembrolizumab
1
lurtotecan
1
liposomal doxorubicin
1
enzalutamide
1
bemiparin
1
belotecan
1
atezolizumab
1
apalutamide
1
alvocidib
1
abiraterone
1
Vinorelbine
1
Tomography, X-Ray Computed
1
Sorafenib
1
Rhenium
1
Radiation
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Carcinoma, Small Cell
×
abiraterone
×
Thoracic
×
Clear all
NCT05551117
2026-02-09
Tamarack
MacroGenics
Phase 2
Terminated
192 enrolled
20 charts